Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management |
| |
Authors: | Stéphanie Gaillard Vered Stearns |
| |
Affiliation: | 1Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, 1650 Orleans Street, CRBI, Room 144, Baltimore, MD 21231, USA |
| |
Abstract: | Aromatase inhibitors are widely used as adjuvant therapy in postmenopausal women with hormone receptor-positive breast cancer. While the agents are associated with slightly improved survival outcomes when compared to tamoxifen alone, bone and musculoskeletal side effects are substantial and often lead to discontinuation of therapy. Ideally, the symptoms should be prevented or adequately treated. This review will focus on bone and musculoskeletal side effects of aromatase inhibitors, including osteoporosis, fractures, and arthralgias. Recent advances have been made in identifying potential mechanisms underlying these effects. Adequate management of symptoms may enhance patient adherence to therapy, thereby improving breast cancer-related outcomes. |
| |
Keywords: | |
本文献已被 PubMed SpringerLink 等数据库收录! |
|